361 related articles for article (PubMed ID: 28142305)
21. Molecular Dynamics Simulations to Investigate How PZM21 Affects the Conformational State of the μ-Opioid Receptor Upon Activation.
Zhao Z; Huang T; Li J
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630190
[TBL] [Abstract][Full Text] [Related]
22. A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain.
Viscusi ER; Webster L; Kuss M; Daniels S; Bolognese JA; Zuckerman S; Soergel DG; Subach RA; Cook E; Skobieranda F
Pain; 2016 Jan; 157(1):264-272. PubMed ID: 26683109
[TBL] [Abstract][Full Text] [Related]
23. In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia.
Bossert JM; Kiyatkin EA; Korah H; Hoots JK; Afzal A; Perekopskiy D; Thomas S; Fredriksson I; Blough BE; Negus SS; Epstein DH; Shaham Y
Biol Psychiatry; 2020 Dec; 88(12):935-944. PubMed ID: 32305216
[TBL] [Abstract][Full Text] [Related]
24. Abuse Potential of Biased Mu Opioid Receptor Agonists.
Negus SS; Freeman KB
Trends Pharmacol Sci; 2018 Nov; 39(11):916-919. PubMed ID: 30343727
[TBL] [Abstract][Full Text] [Related]
25. Some effects of putative G-protein biased mu-opioid receptor agonists in male rhesus monkeys.
Cornelissen JC; Blough BE; Bohn LM; Negus SS; Banks ML
Behav Pharmacol; 2021 Aug; 32(5):453-458. PubMed ID: 33883450
[TBL] [Abstract][Full Text] [Related]
26. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.
Azevedo Neto J; Costanzini A; De Giorgio R; Lambert DG; Ruzza C; Calò G
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854452
[TBL] [Abstract][Full Text] [Related]
27. Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats.
Townsend EA; Blough BE; Epstein DH; Negus SS; Shaham Y; Banks ML
Neuropsychopharmacology; 2022 Nov; 47(12):2132-2139. PubMed ID: 35906489
[TBL] [Abstract][Full Text] [Related]
28. Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of
Kapoor A; Provasi D; Filizola M
Mol Pharmacol; 2020 Oct; 98(4):475-486. PubMed ID: 32680919
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH
Gach-Janczak K; Piekielna-Ciesielska J; Adamska-Bartłomiejczyk A; Wtorek K; Ferrari F; Calo' G; Szymaszkiewicz A; Piasecka-Zelga J; Janecka A
Peptides; 2018 Jul; 105():51-57. PubMed ID: 29684591
[TBL] [Abstract][Full Text] [Related]
30. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers.
Soergel DG; Subach RA; Sadler B; Connell J; Marion AS; Cowan CL; Violin JD; Lark MW
J Clin Pharmacol; 2014 Mar; 54(3):351-7. PubMed ID: 24122908
[TBL] [Abstract][Full Text] [Related]
31. Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats.
Moerke MJ; Negus SS
Neuropharmacology; 2019 Jun; 151():180-188. PubMed ID: 30880123
[TBL] [Abstract][Full Text] [Related]
32. Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.
Soergel DG; Subach RA; Burnham N; Lark MW; James IE; Sadler BM; Skobieranda F; Violin JD; Webster LR
Pain; 2014 Sep; 155(9):1829-1835. PubMed ID: 24954166
[TBL] [Abstract][Full Text] [Related]
33. Oliceridine in the treatment of moderate to severe acute pain.
Eleswarpu SS; Habib AS
Pain Manag; 2021 May; 11(3):237-248. PubMed ID: 33455450
[TBL] [Abstract][Full Text] [Related]
34. Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats.
Townsend EA; Naylor JE; Negus SS; Edwards SR; Qureshi HN; McLendon HW; McCurdy CR; Kapanda CN; do Carmo JM; da Silva FS; Hall JE; Sufka KJ; Freeman KB
Psychopharmacology (Berl); 2017 Sep; 234(17):2597-2605. PubMed ID: 28567699
[TBL] [Abstract][Full Text] [Related]
35. Novel Opioid Receptor Agonists with Reduced Morphine-like Side Effects.
Zhu L; Cui Z; Zhu Q; Zha X; Xu Y
Mini Rev Med Chem; 2018; 18(19):1603-1610. PubMed ID: 30009707
[TBL] [Abstract][Full Text] [Related]
36. Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics.
Grim TW; Acevedo-Canabal A; Bohn LM
Biol Psychiatry; 2020 Jan; 87(1):15-21. PubMed ID: 31806082
[TBL] [Abstract][Full Text] [Related]
37. Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.
Cheng JX; Cheng T; Li WH; Liu GX; Zhu WL; Tang Y
Acta Pharmacol Sin; 2018 Jan; 39(1):154-164. PubMed ID: 29188799
[TBL] [Abstract][Full Text] [Related]
38. Noribogaine is a G-protein biased κ-opioid receptor agonist.
Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
[TBL] [Abstract][Full Text] [Related]
39. Opioid-like adverse effects of tianeptine in male rats and mice.
Baird TR; Akbarali HI; Dewey WL; Elder H; Kang M; Marsh SA; Peace MR; Poklis JL; Santos EJ; Negus SS
Psychopharmacology (Berl); 2022 Jul; 239(7):2187-2199. PubMed ID: 35211768
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antinociceptive actions and tolerance development produced by morphine-fentanyl coadministration: correlation with μ-opioid receptor internalization.
Silva-Moreno A; Gonzalez-Espinosa C; León-Olea M; Cruz SL
Eur J Pharmacol; 2012 Jan; 674(2-3):239-47. PubMed ID: 22079772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
